lovastatin
Brand: Mevacor, Altoprev
Prototype: atorvastatin
Drug Class: HMG-CoA reductase inhibitor (statin)
Drug Family: antilipemic
Subclass: natural statin
Organ Systems: cardiovascular
Mechanism of Action
Competitively inhibits HMG-CoA reductase, the rate-limiting enzyme in hepatic cholesterol synthesis, reducing intracellular cholesterol and upregulating LDL receptors to increase LDL clearance from plasma.
HMG-CoA reductase
Indications
- hypercholesterolemia
- mixed dyslipidemia
- primary prevention of cardiovascular events in select patients
Contraindications
- active liver disease
- unexplained persistent elevations of serum transaminases
- pregnancy
- breastfeeding
- concomitant strong CYP3A4 inhibitors
Adverse Effects
Common
- myalgia
- headache
- GI upset
- elevated transaminases
Serious
- rhabdomyolysis
- myopathy
- hepatotoxicity
Pharmacokinetics (ADME)
| Absorption | approximately 30% absorbed orally; significant first-pass effect; take with evening meal to maximize absorption |
| Distribution | extensive tissue distribution; >95% protein bound |
| Metabolism | extensive hepatic metabolism via CYP3A4 to active metabolites; prodrug (lovastatin acid is active form) |
| Excretion | fecal (~83%) and renal (~10%) |
| Half-life | 2-3 hours |
| Onset | days to weeks for lipid-lowering effect |
| Peak | 2-4 hours |
| Duration | 24 hours with regular dosing |
| Protein Binding | >95% |
| Vd | not well characterized |
Drug Interactions
| Drug / Agent | Mechanism | Severity |
|---|---|---|
| strong CYP3A4 inhibitors (clarithromycin, itraconazole, ketoconazole) | increased lovastatin plasma levels raising myopathy risk | major |
| gemfibrozil | inhibits OATP1B1 and CYP2C8; markedly increases statin exposure | major |
| niacin (high-dose) | additive myopathy risk | moderate |
| amiodarone | CYP3A4 inhibition increases lovastatin exposure | moderate |
Nursing Considerations
- Administer with the evening meal to maximize absorption and efficacy; extended-release tablets should not be crushed.
- Monitor hepatic function tests (ALT/AST) at baseline, 12 weeks after initiation or dose titration, and periodically thereafter; withhold if transaminases exceed 3 times upper limit of normal.
- Instruct patients to report unexplained muscle pain, tenderness, weakness, or dark urine immediately, as these may signal myopathy or rhabdomyolysis; obtain CK level if symptoms arise.
- Counsel women of childbearing age that lovastatin is contraindicated in pregnancy; confirm negative pregnancy status and ensure reliable contraception before initiating therapy.
Clinical Pearls
- Lovastatin is a prodrug; the inactive lactone form is hydrolyzed to the active beta-hydroxy acid in vivo — this distinguishes it from fully active statins such as atorvastatin and rosuvastatin.
- The dose ceiling for lovastatin is lower when used with amiodarone (40 mg/day maximum) due to CYP3A4 interactions; prescribers frequently overlook this constraint in cardiology patients.
Safety Profile
Pregnancy contraindicated
Lactation contraindicated
Renal Adjustment Required
Hepatic Adjustment Required
TDM Not required
Concordance Terms
Cross-referenced clinical concepts — click any term to see all content where it appears.